Xyence in a nutshell
A management company with an excellent financial and scientific profile
Xyence is a management company providing capital and competences to ambitious projects in the field of Life Sciences.
Our Team draws on deep industry expertise, clinical insights and cross-asset class investing experience to drive advances in Life Sciences to improve the lives of patients with unmet medical needs.
The Biopharma opportunity
Revolution in biology
Number and nature of modalities is expanding rapidly
Recent scientific breakthrough in gene editing, stem cells, immuno-oncology, RNA therapy and others are disrupting how we will treat diseases in the coming years.
Avenues to treat existing diseases and unmet clinical needs have been growing exponentially in the last few decades thanks to new biotech modalities, opening up a variety of investment opportunities.
Our Mission
We are a Life Science Company Builder
We support the development of early stage assets targeting unmet clinical needs
-
01
We have a clear investment decision process
This will focus on capital velocity, time-to-exit and de-risking investment opportunities, always maximizing the potential expected returns.
-
02
We invest in european opportunities
Where science and human capital conditions are ideal for investment, and where entry valuations are more attractive than elsewhere.
-
03
Executed by an experienced leadership team
The team experience, international approach and track record will help cherry pick & develop attractive technologies and assets.
A novel model of innovation to lead your research program to a cure for patients
Submit your proposalOur Portfolio
XYence’s Portfolio companies
-
Anabios
Anabios is a US company founded in 2009 in San Diego, specializing in laboratory activities aimed at early evaluation of the potential efficacy and safety of drugs with particular regard to the therapeutic areas of pain, cardiovascular and neurodegenerative diseases.
Fondo: XYence III Health
Data di investimento: Dec 2016
Settore: Healthcare Services-Biotech -
CheckMab
CheckMab is a spin-off of the University of Milan (UniMi) and the National Institute of Molecular Genetics (INGM). The main goal is to generate therapeutic antibodies against tumor-infiltrating regulatory T lymphocytes (Tregs) for a safer immunotherapy against different types of cancer.
Fondo: XYence III Health
Data di investimento: Mar 2018
Settore: Biotech -
Citynews
Citynews is a publishing group that offers an innovative experience in the italian publishing sector thanks to the development of digital technologies capable of offering reliable, real-time and free news.
Fondo: XYence II
Data di investimento: Apr 2011
Settore: Digital publishing -
Clinical Trial Center
Clinical Trial Center SpA (CTC) is the first spin off of the University-Foundation Policlinico Gemelli. CTC offers Site Management Organization (SMO) as well as Contract Research Organization (CRO) services dedicated to pharmaceutical companies and clinical research institutions.
Fondo: XYence III Health
Data di investimento: Aug 2017
Settore: Healthcare Services -
ComfTech
ComfTech, is a startup based in Monza (Italy), which has developed an innovative textile technology that is completely integrated and allows to monitor all the main vital functions. The first healthcare application has a neonatal focus.
Fondo: XYence III Health
Data di investimento: Aug 2018
Settore: Healthcare Services -
CrestOptics
Italian high-tech company founded in 2012 focused on the development and manufacturing of advanced electro-optical instruments including fluorescence microscopy and diagnostic applications.
Fondo: XYence III Health
Data di investimento: Jun 2018
Settore: Medical Devices -
DoveConviene
DoveConviene is an italian geo-localized digital newsstand that makes flyers available from the main retailers and brands in each category, allowing to compare promotions in your area.
Fondo: XYence II
Data di investimento: Apr 2013
Settore: Advertisement -
Enterome
Enterome Bioscience SA is a clinical-stage biotech company based in Paris founded in 2012, active in the development of innovative therapies deriving from the microbiome with particular focus on inflammatory bowel diseases and applications in immuno-oncology.
Fondo: XYence III Health
Data di investimento: Dec 2017
Settore: Biotech -
Gada Group
Gada Group, as the holding company of the group, plans and manages the activities of the commercial and service of the owned companies: EPS - integrated health services, Gada Italia - distributor of innovative medical technologies in the clinical and laboratory fields and Gadamed with a focus in the IOT sector and technical assistance for medical devices and hospital equipments.
Fondo: XYence III Health
Data di investimento: Oct 2018
Settore: Medical Devices-Healthcare Services -
Ixaltis
Ixaltis Sas is a French pharmaceutical company founded in 2012 active in the development of drugs for the treatment of urinary incontinence and urogenital disorders. The most advanced drug, Litoxetine, has completed Phase 2 of development and subsequent regulatory interactions with EMA and FDA.
Fondo: XYence III Health
Data di investimento: May 2016
Settore: Pharmaceutical -
Lambda SpA
Lambda SpA develops advanced laser technologies. Within healthcare, the company operates in the dental sector (Doctor Smile).
Fondo: XYence III Health
Data di investimento: Sep 2019
Settore: Medical Devices -
Neodata Group
Neodata Group researches and develops innovative and customizable technologies for the collection, management and use of Big Data. The company supports Brands, Publishers, Media Agencies and Broadcasters in their Digital Strategy.
Fondo: XYence II
Data di investimento: Feb 2012
Settore: Analytics technology-Big Data -
Pedius
Pedius developed an application for mobile phones to support deaf people in the phone calls, using speech recognition and synthesis technologies.
Fondo: XYence III Health
Data di investimento: Jan 2017
Settore: Digital Health -
Rigenerand
Rigenerand Srl was established in 2009 as a joint venture between Rand Srl (a company active in the biomedical sector) and researchers from the University of Modena and Reggio Emilia. The company is involved in the development of advanced therapies in oncology and innovative medical devices in the cell culture sector.
Fondo: XYence III Health
Data di investimento: Apr 2016
Settore: Biotech-Medical Devices -
Silk Biomaterials
Silk Biomaterials is a clinical-stage regenerative medicine company. It is developing several innovative technology platforms based entirely on natural silk fibroin, which allow for the creation of various biomaterials for endogenous human tissue repair and regeneration.
Fondo: XYence III Health
Data di investimento: Apr 2016
Settore: Medical Devices -
Trifarma
Trifarma SpA, a company specialized in the manufacturing of APIs, quality active ingredients for the pharmaceutical sector, with a specialization in antibiotics and compounds for the nervous system.
Fondo: XYence III Health
Data di investimento: Jul 2017
Settore: Healthcare Services -
Wise
WISE Srl is a Milan- and Berlin-based medical device company developing a new generation of implantable leads for neuromodulation and neuromonitoring. Currently, WISE is clinically validating its WCS electrode for intraoperative neurophysiological monitoring and completing the development of the SCS Expert lead, percutaneously implantable for the stimulation of the spinal cord.
Fondo: XYence III Health
Data di investimento: Jun 2015
Settore: Medical Devices -
Anabios
Anabios is a US company founded in 2009 in San Diego, specializing in laboratory activities aimed at early evaluation of the potential efficacy and safety of drugs with particular regard to the therapeutic areas of pain, cardiovascular and neurodegenerative diseases.
Fondo: XYence III Health
Data di investimento: Dec 2016
Settore: Healthcare Services-Biotech